BiotechTube

Repatha

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke

Trial Timeline

Apr 23, 2021 → Dec 16, 2021

NCT ID
NCT04573777

About Repatha

Repatha is a approved stage product being developed by Amgen for Ischemic Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT04573777. Target conditions include Ischemic Stroke.

What happened to similar drugs?

9 of 13 similar drugs in Ischemic Stroke were approved

Approved (9) Terminated (2) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
🔄Milvexian + PlaceboBristol Myers SquibbPhase 3
🔄Apixaban + WarfarinBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04573777ApprovedTerminated

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
GS-6615 + PlaceboGilead SciencesPhase 1
29